Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501180 | 0.91 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1 | |
| SCHEMBL1861570 | 0.91 | HSP90AA1 (0.65) | HSP90AB1HSP90AA1 | |
| SCHEMBL500954 | 0.91 | HSP90AA1 (0.47) | HSP90AB1HSP90AA1 | |
| SCHEMBL501084 | 0.89 | HSP90AA1 (0.47) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL1866437 | 0.89 | HSP90AA1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL501500 | 0.89 | HSP90AA1 (0.53) | HSP90AB1HSP90AA1 | |
| SCHEMBL501491 | 0.88 | HSP90AA1 (0.48) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL1870020 | 0.87 | HSP90AA1 (0.52) | HSP90AB1HSP90AA1 | |
| SCHEMBL501101 | 0.87 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL1863140 | 0.86 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| EP-2118077-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| EP-2118077-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097640-A2 | TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HSP90B1 1/4885 |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 4/4885 |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.